Extended indication Fruzaqla as monotherapy is indicated for the treatment of adult patients with metastatic colorectal
Therapeutic value No estimate possible yet
Total cost 24,500,000.00
Registration phase Positive CHMP opinion

Product

Registration

Therapeutic value

Expected patient volume per year

Expected cost per patient per year

Potential total cost per year

Off label use

Indication extension

Other information